GSK Relative Valuation
GSK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GSK is overvalued; if below, it's undervalued.
Historical Valuation
GSK plc (GSK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.16 is considered Undervalued compared with the five-year average of 9.91. The fair price of GSK plc (GSK) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 48.97 USD , GSK plc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：48.97
Fair
Undervalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
7.53
EV/EBITDA
GSK plc. (GSK) has a current EV/EBITDA of 7.53. The 5-year average EV/EBITDA is 8.13. The thresholds are as follows: Strongly Undervalued below 4.46, Undervalued between 4.46 and 6.29, Fairly Valued between 9.97 and 6.29, Overvalued between 9.97 and 11.81, and Strongly Overvalued above 11.81. The current Forward EV/EBITDA of 7.53 falls within the Historic Trend Line -Fairly Valued range.
8.61
EV/EBIT
GSK plc. (GSK) has a current EV/EBIT of 8.61. The 5-year average EV/EBIT is 9.44. The thresholds are as follows: Strongly Undervalued below 5.09, Undervalued between 5.09 and 7.26, Fairly Valued between 11.62 and 7.26, Overvalued between 11.62 and 13.79, and Strongly Overvalued above 13.79. The current Forward EV/EBIT of 8.61 falls within the Historic Trend Line -Fairly Valued range.
2.18
PS
GSK plc. (GSK) has a current PS of 2.18. The 5-year average PS is 2.07. The thresholds are as follows: Strongly Undervalued below 1.37, Undervalued between 1.37 and 1.72, Fairly Valued between 2.41 and 1.72, Overvalued between 2.41 and 2.76, and Strongly Overvalued above 2.76. The current Forward PS of 2.18 falls within the Historic Trend Line -Fairly Valued range.
8.10
P/OCF
GSK plc. (GSK) has a current P/OCF of 8.10. The 5-year average P/OCF is 8.45. The thresholds are as follows: Strongly Undervalued below 5.08, Undervalued between 5.08 and 6.76, Fairly Valued between 10.13 and 6.76, Overvalued between 10.13 and 11.81, and Strongly Overvalued above 11.81. The current Forward P/OCF of 8.10 falls within the Historic Trend Line -Fairly Valued range.
12.76
P/FCF
GSK plc. (GSK) has a current P/FCF of 12.76. The 5-year average P/FCF is 12.21. The thresholds are as follows: Strongly Undervalued below 7.45, Undervalued between 7.45 and 9.83, Fairly Valued between 14.59 and 9.83, Overvalued between 14.59 and 16.97, and Strongly Overvalued above 16.97. The current Forward P/FCF of 12.76 falls within the Historic Trend Line -Fairly Valued range.
GSK plc (GSK) has a current Price-to-Book (P/B) ratio of 9.15. Compared to its 3-year average P/B ratio of 4.92 , the current P/B ratio is approximately 85.78% higher. Relative to its 5-year average P/B ratio of 4.91, the current P/B ratio is about 86.36% higher. GSK plc (GSK) has a Forward Free Cash Flow (FCF) yield of approximately 8.86%. Compared to its 3-year average FCF yield of 9.05%, the current FCF yield is approximately -2.02% lower. Relative to its 5-year average FCF yield of 9.69% , the current FCF yield is about -8.49% lower.
9.09
P/B
Median3y
4.92
Median5y
4.91
8.80
FCF Yield
Median3y
9.05
Median5y
9.69
Competitors Valuation Multiple
The average P/S ratio for GSK's competitors is 2.18, providing a benchmark for relative valuation. GSK plc Corp (GSK) exhibits a P/S ratio of 2.18, which is 0.00% above the industry average. Given its robust revenue growth of 10.62%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GSK increased by 45.19% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 0.81 to 25.08.
The secondary factor is the Revenue Growth, contributed 10.62%to the performance.
Overall, the performance of GSK in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is GSK plc (GSK) currently overvalued or undervalued?
What is GSK plc (GSK) fair value?
How does GSK's valuation metrics compare to the industry average?
What is the current P/B ratio for GSK plc (GSK) as of Dec 05 2025?
What is the current FCF Yield for GSK plc (GSK) as of Dec 05 2025?
What is the current Forward P/E ratio for GSK plc (GSK) as of Dec 05 2025?